Notícias e Atividades da Bluebird Bio

Bluebird Bio é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Bluebird Bio é uma empresa listada sob o símbolo BLUE (US).

Veja o organograma con seus 25 executivos principais

Biografias mais buscadas da Bluebird Bio

• Andrew Obenshain, Chief Executive Officer
• Nick Leschly, Director
• John Agwunobi, Director

Recentes movimentos de executivos em Bluebird Bio

• Patrick Cullinan, Vice President, Regulatory Science and Head of Medical Writing & Transparency, deixou a Companhia  (Notícia publicada em 5 de fevereiro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Bluebird Bio.

Bluebird Bio possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Bluebird Bio

• press releases | bluebird bio, Inc.
• FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions | bluebird bio, Inc.
• FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy | bluebird bio, Inc.
• bluebird bio stock trading halted today June 9th and tomorrow June 10th | bluebird bio, Inc.
• bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting | bluebird bio, Inc.
• bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress | bluebird bio, Inc.
• bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) - bluebird bio, Inc.
• bluebird bio to Present at Jefferies Cell Therapy Virtual Summit - bluebird bio, Inc.
• bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency - bluebird bio, Inc.
• U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) - bluebird bio, Inc.
• View more press releases Close

Redes sociais sobre Bluebird Bio

• Bluebird Bio na Wikipedia, Google News e Yahoo Finance
• Bluebird Bio na LinkedIn, Twitter e YouTube